Compare STWD & SRRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STWD | SRRK |
|---|---|---|
| Founded | 2009 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4B | 5.6B |
| IPO Year | 2009 | 2018 |
| Metric | STWD | SRRK |
|---|---|---|
| Price | $18.11 | $49.02 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 12 |
| Target Price | $20.13 | ★ $55.64 |
| AVG Volume (30 Days) | ★ 2.9M | 1.7M |
| Earning Date | 05-08-2026 | 05-13-2026 |
| Dividend Yield | ★ 10.58% | N/A |
| EPS Growth | ★ 4.55 | N/A |
| EPS | ★ 1.15 | N/A |
| Revenue | ★ $1,844,289,000.00 | N/A |
| Revenue This Year | $283.44 | N/A |
| Revenue Next Year | $17.66 | $544.77 |
| P/E Ratio | $15.78 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $16.90 | $27.07 |
| 52 Week High | $20.99 | $51.63 |
| Indicator | STWD | SRRK |
|---|---|---|
| Relative Strength Index (RSI) | 60.90 | 57.33 |
| Support Level | $17.64 | $42.52 |
| Resistance Level | $18.62 | $51.63 |
| Average True Range (ATR) | 0.25 | 1.92 |
| MACD | 0.12 | 0.18 |
| Stochastic Oscillator | 91.92 | 73.07 |
Starwood Property Trust Inc is a real estate investment trust principally engaged in originating, acquiring, and managing commercial mortgage loans, commercial mortgage-backed securities, and other real estate investments in the U.S., Australia, and Europe. The company has four reportable business segments: Commercial and Residential Lending, Infrastructure Lending, Property, and Investing and Servicing. The majority of its revenue is generated from the Commercial and Residential Lending segment, which engages mainly in originating, acquiring, financing, and managing commercial first mortgages, non-agency residential mortgages (residential loans), commercial mortgage-backed securities (CMBS), residential mortgage-backed securities (RMBS), and other real estate and related debt investments.
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.